Reply-Letter to the Editor: What to Do, and What Not to Do, When Diagnosing and Treating Breakthrough Cancer Pain (BTcP): Expert Opinion.
SOD Cure Palliative e Terapia del Dolore, Ospedale Universitario Careggi, Florence, Italy. renato.vellucci@gmail.com.
R
0000-0002-5462-7920
R
Vellucci
SC Anestesia, Rianimazione e Terapia Antalgica, Azienda Ospedaliero-Universitaria di Parma, Parma, Italy.
G
G
Fanelli
Research Centre on Public Health (CESP), University of Milan-Bicocca, Monza, Italy.
P A
PA
Cortesi
Fondazione ANT Italia Onlus, Andria, Italy.
R
R
Pannuti
SC Cure Palliative, Ospedale di Biella, Ponderano, BI, Italy.
C
C
Peruselli
Dipartimento di Farmacia e Biotecnologie, Alma mater studiorum, Università di Bologna, Bologna, Italy.
P
P
Romualdi
D000701:Analgesics, Opioid / Q000627:therapeutic use; D059390:Breakthrough Pain / Q000175:diagnosis; D000072716:Cancer Pain; D005283:Fentanyl / Q000627:therapeutic use; D006801:Humans; D009369:Neoplasms / Q000188:drug therapy
D000701:Analgesics, Opioid; D005283:Fentanyl